Holen Sie sich die Stockscreener-App
1.275
1.19%
0.015
Schlusskurs vom Vortag:
$1.26
Offen:
$1.25
24-Stunden-Volumen:
77,483
Relative Volume:
0.37
Marktkapitalisierung:
$72.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-0.7163
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
-12.67%
1M Leistung:
+12.83%
6M Leistung:
+80.03%
1J Leistung:
-34.78%
1-Tages-Spanne:
$1.20
$1.2898
1-Wochen-Bereich:
$1.15
$1.4969
52-Wochen-Spanne:
$0.6101
$2.01
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Vergleichen Sie PRLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.275 | 71.32M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.43 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.80 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.59 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.89 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Can Prelude Therapeutics Incorporated stock maintain operating marginsEarnings Recap Report & Fast Gaining Stock Reports - newser.com
Is Prelude Therapeutics Incorporated stock a defensive play in 20252025 Trading Recap & Free Daily Entry Point Trade Alerts - newser.com
How moving averages guide Prelude Therapeutics Incorporated tradingInsider Buying & Weekly Market Pulse Alerts - newser.com
Is Prelude Therapeutics Incorporated stock supported by innovation pipelineJuly 2025 Decliners & Expert Verified Stock Movement Alerts - newser.com
Using Bollinger Bands to evaluate Prelude Therapeutics IncorporatedWeekly Trend Report & AI Forecasted Stock Moves - newser.com
Will Prelude Therapeutics Incorporated stock deliver shareholder value2025 Price Targets & High Return Stock Watch Alerts - newser.com
Can Prelude Therapeutics Incorporated stock sustain free cash flow growthQuarterly Profit Summary & Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-09 05:09:32 - newser.com
Can momentum traders help lift Prelude Therapeutics IncorporatedEarnings Summary Report & AI Driven Price Predictions - newser.com
Using economic indicators to assess Prelude Therapeutics Incorporated potentialFed Meeting & Safe Capital Allocation Plans - newser.com
Published on: 2025-10-09 02:10:25 - newser.com
Analyzing Prelude Therapeutics Incorporated with risk reward ratio charts2025 Big Picture & Free Safe Capital Growth Stock Tips - newser.com
CDK4/6 Inhibitor Market Positioned for Remarkable Growth as Revolutionary Therapies Transform Cancer Treatment Landscape in 2024 - Barchart.com
Full technical analysis of Prelude Therapeutics Incorporated stock2025 Bull vs Bear & Daily Growth Stock Investment Tips - newser.com
Will Prelude Therapeutics Incorporated rebound enough to break evenEarnings Risk Report & Fast Momentum Entry Tips - newser.com
Multi asset correlation models including Prelude Therapeutics IncorporatedInsider Buying & Weekly Watchlist for Consistent Profits - newser.com
Will earnings trigger a reversal in Prelude Therapeutics IncorporatedPortfolio Return Summary & Verified Swing Trading Watchlists - newser.com
What drives Prelude Therapeutics Incorporated stock priceSector-Based Investing & Double Digit Trading Ideas - earlytimes.in
Contrasting Cardiol Therapeutics (NASDAQ:CRDL) & Prelude Therapeutics (NASDAQ:PRLD) - Defense World
Prelude Therapeutics (NASDAQ:PRLD) versus Talphera (NASDAQ:TLPH) Financial Contrast - Defense World
3 Promising Penny Stocks With Over $60M Market Cap - simplywall.st
Brokers Set Expectations for PRLD Q3 Earnings - Defense World
Prelude Therapeutics’ (PRLD) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright reiterates Buy rating on Prelude Therapeutics stock with $5 target - Investing.com Canada
Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Buy Rating for PRLD, Price Target at $5.00 | PRLD Stock News - GuruFocus
New PROTACs revealed in Prelude Therapeutics patent - BioWorld MedTech
What momentum shifts mean for Prelude Therapeutics IncorporatedInsider Selling & Weekly Return Optimization Plans - newser.com
Will Prelude Therapeutics Incorporated benefit from macro trendsWeekly Trend Summary & Entry Point Confirmation Signals - newser.com
Statistical indicators supporting Prelude Therapeutics Incorporated’s strength2025 Investor Takeaways & Consistent Growth Stock Picks - newser.com
Visual analytics tools that track Prelude Therapeutics Incorporated performance2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
New Highs: Is Prelude Therapeutics Incorporated stock a good pick for beginnersJuly 2025 Review & Consistent Profit Focused Trading Strategies - خودرو بانک
Profit Recap: Will Prelude Therapeutics Incorporated stock go up in YEARWeekly Trade Analysis & Breakout Confirmation Trade Signals - خودرو بانک
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prelude Therapeutics Inc-Aktie (PRLD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
1.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):